Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
JPH0328408B2 - - Google Patents
[go: Go Back, main page]

JPH0328408B2 - - Google Patents

Info

Publication number
JPH0328408B2
JPH0328408B2 JP56123191A JP12319181A JPH0328408B2 JP H0328408 B2 JPH0328408 B2 JP H0328408B2 JP 56123191 A JP56123191 A JP 56123191A JP 12319181 A JP12319181 A JP 12319181A JP H0328408 B2 JPH0328408 B2 JP H0328408B2
Authority
JP
Japan
Prior art keywords
formula
maxnm
meoh
shoulder
aglycone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP56123191A
Other languages
Japanese (ja)
Other versions
JPS5824538A (en
Inventor
Akihiro Yoshimoto
Hiroyasu Tobe
Tomoyuki Ishikura
Tomio Takeuchi
Hamao Umezawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MERUSHAN KK
Original Assignee
MERUSHAN KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MERUSHAN KK filed Critical MERUSHAN KK
Priority to JP56123191A priority Critical patent/JPS5824538A/en
Publication of JPS5824538A publication Critical patent/JPS5824538A/en
Publication of JPH0328408B2 publication Critical patent/JPH0328408B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Description

【発明の詳細な説明】 本発明は新規なアントラサイクリノン系化合物に
関し、さらに詳しくは下記式 式中、R1が水素原子でR4が水酸基を表わすと
き、R2は基−CH2COOCH3でR3は基−
COCH2CH3もしくは−COCH=C(OH)
CH2CH3を表わすか、またはR2およびR3が一緒
になつて式【式】 【式】もしくは 【式】を表わし; R1が水酸基でR4が水素原子を表わすときR2
よびR3が一緒になつて式【式】を 表わす、 で示されるアントラサイクリノン系化合物に関す
る。該化合物は文献未載の新規物質であつて、優
れた抗腫瘍作用および抗菌作用を示すアントラサ
イクリングリコシド系抗生物質の有機合成中間体
として有用なものである。 従来、下記式 で示されるアントラサイクリノンをアグリコンの
基体骨格とし、主として放線菌によつて生産され
る配糖体であるアントラサイクリン系抗生物質
は、いずれも強い抗菌力並びに抗腫瘍作用を有す
ることが知られている。例えば、アクラシノマイ
シンA(特公昭51−34915号公報参照)、アドリア
マイシン(米国特許第3590028号明細書参照)お
よびダウノマイシン(米国特許第3616242号明細
書参照)は、実験動物腫瘍に対して強い効果を有
するばかりでなく、臨床研究にも使用され、高い
臨床効果が認められている。 一方、微生物が生産しない新種のアントラサイ
クリンの開発を目差した有機合成化学的アプロー
チからの研究成果についても多数の知見が得られ
ている(例えば、F.Arcamome,Topics in
Antibiotic Chemistry,Vol 2,第102〜279頁,
ELLIS HORWOOD LIMITED発行または本発
明者の一部によつて提案された特願昭56−61766
号明細書(特開昭57−17699号公報参照。)参照)。 本発明者らは、さらに優れたアントラサイクリ
ン系抗生物質を見い出すべく各種の微生物の検索
を行つた結果、アクラシノマイシンAの生産菌で
あるストレプトミセス ガリラエウスMA144−
M1(ATCC 31133)の変異菌株が式()で示さ
れる新規アントラサイクリノン系化合物を生産す
ることを見い出し本発明を完成した。 本発明によつて提案される新規化合物は、下記
表によつて具体的に示されるが、本明細書では、
それぞれの化合物を表の最左欄で示す記号にアグ
リコンの語を付して略述する。 【表】 これらの化合物は、いずれも有機合成化学的な
グリコシデーシヨンに供し得る水酸基を複数個有
していることから新規なアントラサイクリンを創
製するための合成中間体として有用な化合物であ
る。 本発明に従えば、これらの化合物は、前述のス
トレプトミセス ガリラエウスMA144−M1を紫
外線等を用いる常法の変異手段(例えば、特開昭
56−49341号公報参照)により得られたストレプ
トミセス ガリラエウスMA144−M1 ANR−58
(微工研菌寄第5081号)を、通常の放線菌による
抗生物質生産に用いられる栄養培地で培養するこ
とによつて得ることができるが、前出のF.
Arcamoneにより文献記載のアグリコン合成法を
改良することによつても製造できる。 以下に本発明を実施例により更に詳細に説明す
る。 実施例 1 可溶性殿粉1.0%,グルコース1.0%,エスサン
ミート(大豆粉,味の素社製)0.1%,酵母エキ
ス0.1%,K2HPO4 0.1%,MgSO4・7H2O 0.1
%,NaCl 0.3%から成る種母用培地100mlを分
注、殺菌した500ml容フラスコ9本に、ストレプ
トミセス ガリラエウスANR−58(微工研菌寄第
5081号)の斜面培養から一白金耳ずつ接種し、28
℃にて48時間振盪培養を行い種母を調製した。 可溶性殿粉1.5%,グルコース1.0%,エスサン
ミート3%,酵母エキス0.2%,K2HPO4 0.1%,
MgSO4・7H2O 0.1%,NaCl 0.3%,CuSO4
5H2O 0.0007%,FeSO4・7H2O 0.0001%,
MnCl2・4H2O 0.0008%およびZnSO4・7H2O
0.0002%(PH7.4)から成る発酵培地15lを分注,
殺菌した30l容ジヤーフアメンター3基に一基当
り上記フラスコ種母3本分を混合接種した。通気
量1/2v.v.m,回転数300/分で3日間培養を実施
した。培養液を混合し遠心操作にて菌体を分離し
採取した。 この菌体にアセトン10lを加え撹拌して生成物
をアセトン中に抽出移行せしめる。次いでアセト
ン抽出層を遠心操作にて集め、およそ1/3量まで
減圧下で濃縮する。これに3のクロロホルムを
添加、抽出した後、濃縮乾涸して粗生成物を得
る。粗生成物をおよそ100mlのメタノールに溶解
し、これにクロマト用シリカゲル(70〜230メツ
シユ,Art.7734 メルク社製)100gを加えてま
ぶし乾燥させる。次いでベンゼンで平衡化した同
一シリカゲルカラム(φ4×26cm)上に重層する。
ベンゼン1.5で流出洗浄させたのちベンゼン/
アセトン/酢酸(200/30/1)3で溶出した。
最初に溶出される色素区分を濃縮乾涸し、得られ
る粗結晶をベンゼンで再結して、58Aアグリコン
の黄色結晶75mgを得た。次いで溶出される第2の
色素区分は濃縮後、分取用シリカゲル薄層
60PF254(メルク社製)に線状に塗布し、クロロホ
ルム/メタノール/濃アンモニア水(90/10/
1)で展開し黄色色素の58Cアグリコン,58Bア
グリコンとワイン赤色素の58Wアグリコンに分離
させた。該当区分をかきとり、クロロホルム/メ
タノール(5/1)混液で抽出し、濃縮乾涸し
た。次いでこれをセフアデツクスLH−20カラム
(φ2.8×42cm)にかけメタノールで溶出して精製
し、濃縮乾涸し、58Cアグリコンの黄色粉末250
mgと58Bアグリコンの黄色結晶53mg及び58Wアグ
リコンのワイン赤粉末70mgを取得した。一方、上
述のシリカゲルカラムクロマトで得られる第3の
色素区分は濃縮することにより容易に結晶し、
過にて集積し、真空乾燥することにより58Gアグ
リコンの黄褐色結晶830mgを得た。第4の色素区
分は58Gアグリコンと同様に処理し、58Jアグリ
コンの黄色粉末87mgを得た。 以下に上記で取得したアグリコンの理化学的性
状を示す。 58Aアグリコン (1)形 状 黄色針状晶 (2)融 点 250〜252℃ (3)分子量 384 (4)元素分析 C20H16O8として C H O 計算値% 62.50 4.20 33.30 実験値 62.30 4.32 33.41 (5)紫外・可視スペクトル λ90%MeOH maxnm(E1% 1cm):
230(855),250(肩,635), 290(640),42(325) λ90%MeOH−0.1NHCl maxnm(E1% 1cm):
230(910),250(肩,625), 287(720),438(400) λ90%MeOH−0.1NNaOH maxnm(E1% 1cm):
297(895),390(240), 545(550) (6)IR(KBr)cm-1:3270,1730,1700,1620,
1470,1320,1260,1240,1160,760 (7)PMRスペクトラム(100MHz,DMSO−d6
δppn: 11.9(1H,broad,水素結合),8.2(1H,s,水
素結合),7.53(1H,s,Ar−H),7.03(1H,
d,J=2,Ar−H),6.5(1H,d,J=2,
Ar−H),3.7(2H,s,−CH2−)3.6(3H,s,−
COOCH3 ),2・85(2H,q,J=7,
【式】)1.0(3H,t,J=7,−CH2CH3) 58Bアグリコン (1)形 状 黄色針状晶 (2)融 点 208〜210℃ (3)分子量 426 (4)元素分析 C22H18O9として C H O 計算値(%) 61.97 4.26 33.77 実験値 62.04 4.24 33.67 (5)紫外・可視スペクトル λ90%MeOH maxnm(E1% 1cm):
203(360),235(355), 287(435),440(180) λ90%MeOH−0.1NHCl maxnm(E1% 1cm):
203(430),235(410), 286(480),440(200) λ90%MeOH−0.1NNaOH maxnm(E1% 1cm):
210(1950),245(肩,420),302(605), 380(235),570(205) (6)IR(KBr)cm-1:3270,2950,1700,1620,
1600,1470,1420,1330,1260,1240,1160,
1100,760 (7)PMRスペクトル (100MHz,重クロロホルム−重メタノール混液)
δppn: 7.66(1H,s,Ar−H),7.20(1H,d,J=
2,Ar−H),6.50(1H,d,J=2,Ar−H),
3.88(1H,s,−C=),3.84(2H,s,−CH2
−),3.72(3H,s,−COOCH3),2.48(2H,q,
J=7,【式】),1.22(3H,t,J= 7,−CH2CH3) 58Cアグリコン (1)形 状 黄色粉末 (2)融 点 165〜167℃ (3)分子量 412 (4)元素分析 C22H20O8として C H O 計算値(%) 64.07 4.89 31.04 実験値 63.81 4.91 31.30 (5)紫外・可視スペクトル λ90%MeOH maxnm(E1% 1cm):
225(690),256(440), 274(470),294(380), 305(肩,320),440(255) λ90%MeOH−0.1NHCl maxnm(E1% 1cm):
226(775),256(肩,425), 274(550),290(肩,420), 305(肩,270),440(295) λ90%MeOH−0.1NNaOH maxnm(E1% 1cm):
235(肩,650), 255(肩,410),298(475), 310(肩,460),523(255) (6)IR(KBr)cm-1:3500,1720,1625,1605,
1400,1260,1180,1020,755 (7)PMRスペクトラム (100MHz,CDCl3とCD3OD混液)δppn: 7.5(1H,s,Ar−H),7.15(1H,d,J=
2,Ar−H),6.55(1H,d,J=2,Ar−H),
3.9(1H,s,H−10位),3.65(3H,s,−COOC
H3),2.9(2H,t,J=4,H−7位),2.3
(2H,t,J=4,H−8位),1.6(2H,q,J
=7,−CH2 CH3),1.05(3H,t,J=7,−
CH2CH3 ) 58Gアグリコン (1)形 状 黄色結晶 (2)融 点 250℃(分解) (3)分子量 394 (4)元素分析 C21H14O8として C H O 計算値(%) 63.96 3.58 32.46 実験値 64.33 3.55 31.97 (5)紫外・可視スペクトル λ90%MeOH maxnm(E1% 1cm):
215(肩,815),225(855), 252(535),290(740), 443(325) λ90%MeOH−0.1NHCl maxnm(E1% 1cm):
205(710),222(800), 290(765),443(330) λ90%MeOH−0.1NNaOH maxnm(E1% 1cm):
295(670),315(620), 542(325) (6)IR(KBr)cm-1:3200,3000〜2300,1670,
1620,1470,1280,1160,1100,850 (7)PMRスペクトラム(100MHz,DMSO−d6
δppn: 12.6(1H,s,水素結合),11.9(1H,s,水素
結合),7.5(1H,d,J=2,Ar−H),6.5
(1H,d,J=2,Ar−H),6.3(1H,d,J=
2,【式】),5.45(1H,d,J=2,−H), 2.6(2H,q,J=7,【式】),1.2 (3H,t,J=7,−CH2CH3 ) 58Jアグリコン (1)形 状 黄色結晶 (2)融 点 270℃(分解) (3)分子量 394 (4)元素分析 C21H14O8として C H O 計算値(%) 63.96 3.58 32.46 実験値 64.01 3.55 32.40 (5)紫外・可視スペクトル λ90%MeOH maxnm(E1% 1cm):
214(700),287(920), 425(140) λ90%MeOH−0.1NHCl maxnm(E1% 1cm):
202(520),215(600), 288(860),425(140) λ90%MeOH−0.1NNaOH maxnm(E1% 1cm):
211(2220),312(1030), 390(170),515(140) (6)IR(KBr)cm-1:3400,3200,3000〜2500,
1690(肩),1670,1630,1580,1440,1400,
1320,1265,1210,1175,1115,850,630 (7)PMRスペクトル(100MHz,DMSO−d6
δppn: 13.12(1H,s,水素結合)12〜10.5(2H,,
broad,水素結合),7.64(1H,s,Ar−H),
7.03(1H,d,J=2,Ar−H),6.55(1H,d,
J=2,Ar−H),6.24(1H,d,J=2,
【式】),5.45(1H,d,J=2,−H),3.08 (2H,q,J=7,【式】)1.20(3H, t,J=7,−CH2CH3 ) 58Wアグリコン (1)形 状 赤紫針状晶 (2)融 点 293〜295℃ (3)分子量 408 (4)元素分析 C22H16O8として C H O 計算値(%) 64.70 3.95 31.35 実験値 64.57 4.01 31.50 (5)紫外・可視スペクトル λ90%MeOH maxnm(E1% 1cm):
244(380),275(340), 300(肩,275),520(295) λ90%MeOH−0.1NHCl maxnm(E1% 1cm):
246(535),272(635), 285(210) λ90%MeOH−0.1NNaOH maxnm(E1% 1cm):
218(765),247(1200), 285(肩,505),313(710), 372(255),388(255), 545(415) (6)IR(KBr)cm-1:3275,1725,1620,1570,
1410,1285,1190,760,600 (7)PMRスペクトラム(100MHz,DMSO−d6
δppn: 7.85(1H,s,Ar−H),7.18(1H,d,J=
2,Ar−H),6.96(1H,s,Ar−H),6.60
(1H,d,J=2,Ar−H),3.98(3H,s,−
COOCH3 ),2.65(2H,q,J=7,
【式】),1.2(3H,t,J=7,− CH2CH3
DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a novel anthracyclinone compound, and more specifically, In the formula, when R 1 is a hydrogen atom and R 4 is a hydroxyl group, R 2 is a group -CH 2 COOCH 3 and R 3 is a group -
COCH 2 CH 3 or -COCH=C(OH)
CH 2 CH 3 or R 2 and R 3 together represent the formula [Formula] [Formula] or [Formula]; When R 1 is a hydroxyl group and R 4 is a hydrogen atom, R 2 and R It relates to an anthracyclinone compound represented by, where 3 taken together represents the formula [Formula]. This compound is a new substance that has not been described in any literature and is useful as an intermediate in the organic synthesis of anthracycline glycoside antibiotics that exhibit excellent antitumor and antibacterial effects. Conventionally, the following formula Anthracycline antibiotics, which are glycosides mainly produced by actinomycetes and have anthracyclinone as the basic skeleton of the aglycone, are known to have strong antibacterial and antitumor effects. There is. For example, aclacinomycin A (see Japanese Patent Publication No. 51-34915), adriamycin (see US Pat. No. 3,590,028), and daunomycin (see US Pat. No. 3,616,242) have strong effects on tumors in experimental animals. In addition to being used in clinical research, it has been recognized to have high clinical efficacy. On the other hand, a large amount of research results have been obtained from organic synthetic chemical approaches aimed at developing new types of anthracyclines that are not produced by microorganisms (for example, F. Arcamome, Topics in
Antibiotic Chemistry, Vol 2, pp. 102-279,
Patent application No. 1976-61766 published by ELLIS HORWOOD LIMITED or proposed by some of the inventors
(See Japanese Patent Application Laid-open No. 17699/1983). The present inventors conducted a search for various microorganisms in order to find even better anthracycline antibiotics, and as a result, they found Streptomyces galilaeus MA144-, which is a producer of aclacinomycin A.
The inventors discovered that a mutant strain of M 1 (ATCC 31133) produces a novel anthracyclinone compound represented by the formula (), and completed the present invention. The novel compounds proposed by the present invention are specifically shown in the table below, and herein,
Each compound is briefly described by adding the word aglycone to the symbol shown in the leftmost column of the table. [Table] These compounds are useful as synthetic intermediates for creating new anthracyclines because they all have multiple hydroxyl groups that can be subjected to organic synthetic chemical glycosidation. . According to the present invention, these compounds can be obtained by mutating the aforementioned Streptomyces galilaeus MA144-M 1 using conventional mutagenesis methods such as ultraviolet light (e.g.
Streptomyces galilaeus MA144-M 1 ANR-58 obtained by
(Feikoken Bacteria No. 5081) can be obtained by culturing it in a nutrient medium used for the production of antibiotics by ordinary actinomycetes, but the above-mentioned F.
It can also be produced by modifying the aglycone synthesis method described in the literature using Arcamone. The present invention will be explained in more detail below using Examples. Example 1 Soluble starch 1.0%, glucose 1.0%, Ssanmeat (soybean flour, manufactured by Ajinomoto Co., Ltd.) 0.1%, yeast extract 0.1%, K 2 HPO 4 0.1%, MgSO 4 7H 2 O 0.1
%, NaCl 0.3% was dispensed into nine sterilized 500 ml flasks.
Inoculate one platinum loopful from the slant culture of No. 5081), and
A seed mother was prepared by culturing with shaking at ℃ for 48 hours. Soluble starch 1.5%, glucose 1.0%, Essanmeat 3%, yeast extract 0.2%, K 2 HPO 4 0.1%,
MgSO47H2O 0.1%, NaCl 0.3%, CuSO4
5H 2 O 0.0007%, FeSO 4・7H 2 O 0.0001%,
MnCl24H2O 0.0008% and ZnSO47H2O
Dispense 15l of fermentation medium consisting of 0.0002% (PH7.4),
Three sterilized 30-liter jar fermenters were mixed and inoculated with the amount of the above-mentioned three flask seeds per container. Culture was carried out for 3 days at an aeration rate of 1/2 v.vm and a rotation speed of 300/min. The culture solution was mixed and the bacterial cells were separated and collected by centrifugation. Add 10 liters of acetone to the bacterial cells and stir to extract and transfer the product into the acetone. Next, the acetone extract layer is collected by centrifugation and concentrated under reduced pressure to approximately 1/3 of its volume. After adding chloroform (3) to this and extracting, the mixture was concentrated to dryness to obtain a crude product. The crude product is dissolved in approximately 100 ml of methanol, 100 g of chromatographic silica gel (70-230 mesh, Art. 7734, manufactured by Merck & Co., Ltd.) is added thereto, and the mixture is sprinkled and dried. Then, layer it on the same silica gel column (φ4 x 26 cm) equilibrated with benzene.
After cleaning the spill with benzene 1.5, benzene/
Elution was carried out with acetone/acetic acid (200/30/1) 3.
The first eluted dye fraction was concentrated to dryness, and the resulting crude crystals were recrystallized with benzene to obtain 75 mg of yellow crystals of 58A aglycone. The second dye fraction to be eluted is then concentrated and transferred to a thin layer of preparative silica gel.
60PF 254 (manufactured by Merck & Co.) in a linear manner and chloroform/methanol/concentrated ammonia water (90/10/
It was developed in step 1) and separated into 58C and 58B aglycones, which are yellow pigments, and 58W aglycones, which are wine red pigments. The relevant section was scraped off, extracted with a chloroform/methanol (5/1) mixture, and concentrated to dryness. This was then purified by applying it to a Cephadex LH-20 column (φ2.8 x 42 cm) and eluting with methanol, and concentrating to dryness.
53 mg of yellow crystals of 58B aglycone and 70 mg of wine red powder of 58W aglycone were obtained. On the other hand, the third dye fraction obtained by the above-mentioned silica gel column chromatography is easily crystallized by concentration.
The mixture was collected by filtration and dried under vacuum to obtain 830 mg of yellowish brown crystals of 58G aglycon. The fourth dye fraction was treated in the same manner as the 58G aglycone, yielding 87 mg of yellow powder of the 58J aglycone. The physical and chemical properties of the aglycon obtained above are shown below. 58A aglycone (1) Shape Yellow needle crystals (2) Melting point 250-252℃ (3) Molecular weight 384 (4) Elemental analysis C 20 H 16 O 8 as CHO Calculated value % 62.50 4.20 33.30 Experimental value 62.30 4.32 33.41 (5) Ultraviolet/visible spectrum λ90%MeOH maxnm (E1% 1cm):
230 (855), 250 (shoulder, 635), 290 (640), 42 (325) λ90%MeOH−0.1NHCl maxnm (E1% 1cm):
230 (910), 250 (shoulder, 625), 287 (720), 438 (400) λ90%MeOH−0.1NNaOH maxnm (E1% 1cm):
297 (895), 390 (240), 545 (550) (6) IR (KBr) cm -1 : 3270, 1730, 1700, 1620,
1470, 1320, 1260, 1240, 1160, 760 (7) PMR spectrum (100MHz, DMSO−d 6 )
δ ppn : 11.9 (1H, broad, hydrogen bond), 8.2 (1H, s, hydrogen bond), 7.53 (1H, s, Ar-H), 7.03 (1H,
d, J=2, Ar-H), 6.5 (1H, d, J=2,
Ar-H), 3.7 (2H, s, -CH 2 -) 3.6 (3H, s, -
COOC H 3 ), 2・85 (2H, q, J=7,
[Formula]) 1.0 (3H, t, J=7, -CH 2 C H 3 ) 58B aglycon (1) Shape Yellow needle crystals (2) Melting point 208-210℃ (3) Molecular weight 426 (4) Element Analysis As C 22 H 18 O 9 C H O Calculated value (%) 61.97 4.26 33.77 Experimental value 62.04 4.24 33.67 (5) Ultraviolet/visible spectrum λ90%MeOH maxnm (E1% 1cm):
203 (360), 235 (355), 287 (435), 440 (180) λ90%MeOH−0.1NHCl maxnm (E1% 1cm):
203 (430), 235 (410), 286 (480), 440 (200) λ90%MeOH−0.1NNaOH maxnm (E1% 1cm):
210 (1950), 245 (shoulder, 420), 302 (605), 380 (235), 570 (205) (6) IR (KBr) cm -1 : 3270, 2950, 1700, 1620,
1600, 1470, 1420, 1330, 1260, 1240, 1160,
1100, 760 (7) PMR spectrum (100MHz, heavy chloroform-heavy methanol mixture)
δ ppn : 7.66 (1H, s, Ar-H), 7.20 (1H, d, J=
2, Ar-H), 6.50 (1H, d, J=2, Ar-H),
3.88 (1H, s, -H C=), 3.84 (2H, s, -CH 2
−), 3.72 (3H, s, −COOCH 3 ), 2.48 (2H, q,
J = 7, [Formula]), 1.22 (3H, t, J = 7, -CH 2 CH 3 ) 58C aglycone (1) Shape Yellow powder (2) Melting point 165-167℃ (3) Molecular weight 412 (4) ) Elemental analysis C 22 H 20 O 8 as C H O Calculated value (%) 64.07 4.89 31.04 Experimental value 63.81 4.91 31.30 (5) Ultraviolet/visible spectrum λ90%MeOH maxnm (E1% 1cm):
225 (690), 256 (440), 274 (470), 294 (380), 305 (shoulder, 320), 440 (255) λ90%MeOH-0.1NHCl maxnm (E1% 1cm):
226 (775), 256 (shoulder, 425), 274 (550), 290 (shoulder, 420), 305 (shoulder, 270), 440 (295) λ90%MeOH−0.1NNaOH maxnm (E1% 1cm):
235 (shoulder, 650), 255 (shoulder, 410), 298 (475), 310 (shoulder, 460), 523 (255) (6)IR (KBr) cm -1 : 3500, 1720, 1625, 1605,
1400, 1260, 1180, 1020, 755 (7) PMR spectrum (100MHz, CDCl 3 and CD 3 OD mixture) δ ppn : 7.5 (1H, s, Ar-H), 7.15 (1H, d, J=
2, Ar-H), 6.55 (1H, d, J=2, Ar-H),
3.9 (1H, s, H-10th position), 3.65 (3H, s, -COOC
H 3 ), 2.9 (2H, t, J=4, H-7 position), 2.3
(2H, t, J = 4, H-8 position), 1.6 (2H, q, J
=7, -C H 2 CH 3 ), 1.05 (3H, t, J = 7, -
CH 2 C H 3 ) 58G aglycon (1) Shape Yellow crystal (2) Melting point 250℃ (decomposition) (3) Molecular weight 394 (4) Elemental analysis C 21 H 14 O 8 C H O Calculated value (%) 63.96 3.58 32.46 Experimental value 64.33 3.55 31.97 (5) Ultraviolet/visible spectrum λ90%MeOH maxnm (E1% 1cm):
215 (shoulder, 815), 225 (855), 252 (535), 290 (740), 443 (325) λ90%MeOH−0.1NHCl maxnm (E1% 1cm):
205 (710), 222 (800), 290 (765), 443 (330) λ90%MeOH−0.1NNaOH maxnm (E1% 1cm):
295 (670), 315 (620), 542 (325) (6) IR (KBr) cm -1 : 3200, 3000~2300, 1670,
1620, 1470, 1280, 1160, 1100, 850 (7) PMR spectrum (100MHz, DMSO−d 6 )
δ ppn : 12.6 (1H, s, hydrogen bond), 11.9 (1H, s, hydrogen bond), 7.5 (1H, d, J=2, Ar-H), 6.5
(1H, d, J=2, Ar-H), 6.3 (1H, d, J=
2, [Formula]), 5.45 (1H, d, J=2, -H), 2.6 (2H, q, J=7, [Formula]), 1.2 (3H, t, J=7, -CH 2 C H 3 ) 58J aglycon (1) Shape Yellow crystal (2) Melting point 270℃ (decomposed) (3) Molecular weight 394 (4) Elemental analysis C 21 H 14 O 8 as CHO Calculated value (%) 63.96 3.58 32.46 Experimental value 64.01 3.55 32.40 (5) Ultraviolet/visible spectrum λ90%MeOH maxnm (E1% 1cm):
214 (700), 287 (920), 425 (140) λ90%MeOH-0.1NHCl maxnm (E1% 1cm):
202 (520), 215 (600), 288 (860), 425 (140) λ90%MeOH−0.1NNaOH maxnm (E1% 1cm):
211 (2220), 312 (1030), 390 (170), 515 (140) (6) IR (KBr) cm -1 : 3400, 3200, 3000~2500,
1690 (shoulder), 1670, 1630, 1580, 1440, 1400,
1320, 1265, 1210, 1175, 1115, 850, 630 (7) PMR spectrum (100MHz, DMSO−d 6 )
δ ppn : 13.12 (1H, s, hydrogen bond) 12 to 10.5 (2H, ,
broad, hydrogen bond), 7.64 (1H, s, Ar-H),
7.03 (1H, d, J=2, Ar-H), 6.55 (1H, d,
J=2, Ar-H), 6.24 (1H, d, J=2,
[Formula]), 5.45 (1H, d, J=2, -H), 3.08 (2H, q, J=7, [Formula]) 1.20 (3H, t, J=7, -CH 2 C H 3 ) 58W aglycon (1) Shape Red-purple needle crystal (2) Melting point 293-295℃ (3) Molecular weight 408 (4) Elemental analysis C 22 H 16 O 8 as CHO Calculated value (%) 64.70 3.95 31.35 Experiment Value 64.57 4.01 31.50 (5) Ultraviolet/visible spectrum λ90%MeOH maxnm (E1% 1cm):
244 (380), 275 (340), 300 (shoulder, 275), 520 (295) λ90%MeOH−0.1NHCl maxnm (E1% 1cm):
246 (535), 272 (635), 285 (210) λ90%MeOH−0.1NNaOH maxnm (E1% 1cm):
218 (765), 247 (1200), 285 (shoulder, 505), 313 (710), 372 (255), 388 (255), 545 (415) (6) IR (KBr) cm -1 : 3275, 1725 , 1620, 1570,
1410, 1285, 1190, 760, 600 (7) PMR spectrum (100MHz, DMSO−d 6 )
δ ppn : 7.85 (1H, s, Ar-H), 7.18 (1H, d, J=
2, Ar-H), 6.96 (1H, s, Ar-H), 6.60
(1H, d, J=2, Ar-H), 3.98 (3H, s, -
COOC H 3 ), 2.65 (2H, q, J=7,
[Formula]), 1.2 (3H, t, J=7, - CH 2 C H 3 )

Claims (1)

【特許請求の範囲】 1 式 式中、R1が水素原子でR4が水酸基を表わすと
き、R2は基−CH2COOCH3でR3は基−
COCH2CH3もしくは−COCH=C(OH)
CH2CH3を表わすか、またはR2およびR3が一緒
になつて式【式】 【式】もしくは 【式】を表わし; R1が水酸基でR4が水素原子を表わすときR2
よびR3が一緒になつて式【式】を 表わす、 で示される化合物。
[Claims] 1 formula In the formula, when R 1 is a hydrogen atom and R 4 is a hydroxyl group, R 2 is a group -CH 2 COOCH 3 and R 3 is a group -
COCH 2 CH 3 or -COCH=C(OH)
CH 2 CH 3 or R 2 and R 3 together represent the formula [Formula] [Formula] or [Formula]; When R 1 is a hydroxyl group and R 4 is a hydrogen atom, R 2 and R A compound represented by, where 3 taken together represents the formula [formula].
JP56123191A 1981-08-06 1981-08-06 Novel anthracyclinone compound Granted JPS5824538A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP56123191A JPS5824538A (en) 1981-08-06 1981-08-06 Novel anthracyclinone compound

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP56123191A JPS5824538A (en) 1981-08-06 1981-08-06 Novel anthracyclinone compound

Publications (2)

Publication Number Publication Date
JPS5824538A JPS5824538A (en) 1983-02-14
JPH0328408B2 true JPH0328408B2 (en) 1991-04-19

Family

ID=14854440

Family Applications (1)

Application Number Title Priority Date Filing Date
JP56123191A Granted JPS5824538A (en) 1981-08-06 1981-08-06 Novel anthracyclinone compound

Country Status (1)

Country Link
JP (1) JPS5824538A (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT507298B1 (en) * 2009-05-29 2010-04-15 Sealife Pharma Gmbh NEW ANTHRACINE DERIVATIVES
CN110627640B (en) * 2017-09-19 2020-10-30 浙江大学 Preparation and medical application of streptomyces xanthioides acid and streptomyces xanthione

Also Published As

Publication number Publication date
JPS5824538A (en) 1983-02-14

Similar Documents

Publication Publication Date Title
CA1156578A (en) Rhodomycin-group of antibiotics and process for preparing same
US4064014A (en) Antibiotic compounds marcellomycin and musettamycin
YOSHIMOTO et al. Intensely potent anthracycline antibiotic oxaunomycin produced by a blocked mutant of the daunorubicin-producing microorganism
EP0014853B1 (en) Anthracycline derivatives, a process for their preparation and pharmaceutical compositions containing them
CA1206472A (en) Anthracyclinone glycosides and their preparation method
US4329339A (en) Anthracyclinones and derivatives thereof
US4303785A (en) Antitumor anthracycline antibiotics
US4471052A (en) Biosynthesis of simplified anthracyclines
US4734493A (en) Novel anthracycline antibiotics
US4127714A (en) Anthracycline glycosides
EP0030255B1 (en) 2-hydroxyaclacinomycin a, pharmaceutical composition containing it; 2-hydroxyaclavinone and fermentative process for preparing same
US4612371A (en) Anthracycline antibiotics
DK146342B (en) METHOD FOR PREPARING ANTHRACYCLING LYCOSID ANTIBIOTICS DESIGNED MA 144-M1 AND MA 144-M2 OR NOT TOXIC ACID ADDITION SALTS OR COMPLEXES THEREOF WITH DESOXYRIBONUCLEIC ACID
JPH0328408B2 (en)
EP0275966B1 (en) A doxorubicin derivative, a process for preparing the same, pharmaceutical preparations comprising the same, and the use of the same for the manufacture of useful medicaments
US4401812A (en) Anthracycline antibiotics
US4918172A (en) Anthracycline antibiotics
JOHDO et al. ANTHRACYCLINE METABOLITES FROM Streptomyces violaceus A262 III. NEW ANTHRACYCLINE OBELMYCINS PRODUCED BY A VARIANT STRAIN SE2-2385
JPH0479355B2 (en)
EP0083019A2 (en) Process for optically active anthracycline glycosides, the novel 4-deoxy-aclacinomycins A and B and pharmaceutical preparations
JP3074084B2 (en) Novel 16-membered macrolide derivatives and production method
US4123608A (en) Antibiotic compound
JPH0576958B2 (en)
JP4443740B2 (en) Anthracycline antibiotics
JP4342048B2 (en) Antibiotics tuberacutomycin B, D and E and methods for their production